Literature DB >> 6776810

Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition.

J L Preud'homme, L Morel-Maroger, J C Brouet, M Cerf, F Mignon, P Guglielmi, M Seligmann.   

Abstract

Three patients presented with renal or more diffuse tissue deposits of a nonamyloid material reactive with anti-kappa antibody by immunofluorescence. All patients had progressive renal failure with the nephrotic syndrome and extensive tubular basement membrane deposits. Glomerular lesions were conspicuous but heterogeneous. One patient also had hepatic deposits with peliosis at histopathologic examination. An underlying lymphoplasmacytic disorder was found in all patients: multiple myeloma in one, pleomorphic lymphoplasmacytic malignancy analogous to Waldenström's macroglobulinemia in one and bone marrow monoclonal plasmacytosis without overt myeloma in one. Biosynthesis experiments in two cases showed production of abnormal kappa chains which were not detected in appreciable amounts in serum and urine. These light chains had an aberrant size (abnormally short or large), their apparent molecular weight was larger in secretion than in cytoplasmic extracts (suggesting their glycosylation) and they were secreted as polymers. These results suggest a causal relationship between production of abnormal light chains and tissue deposition.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776810     DOI: 10.1016/0002-9343(80)90421-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

1.  Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

Authors:  J Buxbaum
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

2.  In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy.

Authors:  C Delaporte; B Varet; M Fardeau; D Nochy; A Ract
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease.

Authors:  A A Khamlichi; P Aucouturier; C Silvain; M Bauwens; G Touchard; J L Preud'homme; F Nau; M Cogné
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

4.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

5.  Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease.

Authors:  A Rocca; A A Khamlichi; P Aucouturier; L H Noël; L Denoroy; J L Preud'homme; M Cogné
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

6.  Light chains and the kidney.

Authors:  J R Bradley; S Thiru; D B Evans
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

7.  Systemic and rapidly progressive light-chain deposition disease initially presenting as tubulointerstitial nephritis.

Authors:  Satoko Takahashi; Jun Soma; Izaya Nakaya; Mayumi Yahata; Tsutomu Sakuma; Hiroshi Yaegashi; Akiyoshi Sato; Masaharu Wano; Hiroshi Sato
Journal:  CEN Case Rep       Date:  2012-07-19

8.  Renal and systemic kappa light chain deposits and their plasma cell origin identified by immunoelectron microscopy.

Authors:  M M Silver; S A Hearn; S Ritchie; R P Slinger; J A Sholdice; P S Cordy; A B Hodsman
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

9.  Bone marrow lambda-type light chain crystalline structures associated with multiple myeloma.

Authors:  H Schvartz; P Bonhomme; S Caulet; A Beorchia; M Patey; T Caulet
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 10.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.